Navigation Links
It's Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
Date:9/11/2007

PARAMUS, N.J., Sept. 11 /PRNewswire-USNewswire/ -- If you have or have ever had chronic heartburn, you may be at risk for Barrett's esophagus, a serious complication of chronic, severe gastroesophageal reflux disease (GERD). Barrett's esophagus has been recognized as a major risk factor for developing cancer of the esophagus, the seventh deadliest cancer in men in the United States.

Barrett's esophagus is marked by cellular changes in the lining of the esophagus, which can progress to low-grade, and then high-grade dysplasia -- a level that is highly pre-malignant. These abnormal cellular changes can lead to a type of cancer called esophageal adenocarcinoma, the fastest rising malignancy in the United States, according to the National Institutes of Health.

The Valley Hospital's Center for Barrett's Esophagus and GERD provides cutting-edge diagnostic, treatment, management, and research services for these related conditions. The Center is one of the most comprehensive on the East Coast and unique to northern New Jersey. The physician team includes board-certified gastroenterologists and thoracic surgeons.

Diagnostic and treatment methods available at the Center include endoscopy, medications to reduce acid, minimally invasive surgical procedures to repair hiatal hernias and to prevent acid reflux, radiofrequency ablation to destroy abnormal cells, endoscopic mucosal resection to remove nodules within Barrett's esophagus, and esophageal cancer surgery.

Robert J. Korst, M.D., Medical Director of The Valley Hospital's Daniel and Gloria Blumenthal Cancer Center, and Director of Thoracic Surgery, says he and physicians at the Center for Barrett's Esophagus and GERD must take a two-prong approach to treating Barrett's esophagus that both destroys the abnormal lining and stops acid reflux.

"Radiofrequency ablation can get rid of the lining, but if the GERD is not controlled, those abnormal cells can grow back and put the patient at risk for cancer once again," he adds.

If Barrett's esophagus progresses into high-grade dysplasia or cancer, the entire esophagus must be removed. Dr. Korst specializes in the treatment and research of esophageal cancer and is highly experienced in using both laparoscopic and traditional surgical methods to remove the esophagus and construct a new one by stretching the stomach.

Barrett's esophagus is most prevalent in middle-aged and elderly Caucasian men but can affect anyone, even those who do not have obvious symptoms of gastroesophageal reflux disease. To learn more about Barrett's esophagus or to schedule an appointment for an evaluation, call The Valley Hospital Center for Barrett's Esophagus and GERD at 201-634-5789


'/>"/>
SOURCE The Valley Hospital
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
5. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
8. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
9. Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
10. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
11. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... June 26, 2016 Story ... operating models within the health care industry is causing ... efficiency , Deloitte offers a suite of solutions ... issues impacting efficient cost optimization: labor resource analysis, revenue ... services facilitate better outcomes and better economics ...
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
Breaking Medicine News(10 mins):